Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 8
- Registration Number
- NCT06671873
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, China
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 60
- Registration Number
- NCT06601504
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
- Conditions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 412
- Registration Number
- NCT06584032
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 98
- Registration Number
- NCT06387082
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, China
🇨🇳Anhui Provincial Hospital, Hefei, China
A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 316
- Registration Number
- NCT06387069
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 482
- Registration Number
- NCT06361888
- Locations
- 🇨🇳
Nanjing Tianyinshan Hospital, Nanjing, Jiang Su, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 48
- Registration Number
- NCT06291415
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington (UW) Medical Center, Seattle, Washington, United States
🇦🇺The Perth Blood Institute (PBI) Hollywood Specialist Centre, West Perth, Western Australia, Australia
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 24
- Registration Number
- NCT05930119
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 81
- Registration Number
- NCT05886374
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 6
- Registration Number
- NCT05781906
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China